Back to blogComparison

TheyTest vs. Xobin: Which Budget Skills Assessment Tool Fits Your Region?

August 12, 20264 min readTheyTest Team
TheyTest vs. Xobin: Which Budget Skills Assessment Tool Fits Your Region?

Xobin is positioned as a lower-cost, self-serve skills assessment platform, part of the same budget-tier category as several other testing tools. For teams comparing options mainly on price, it's worth also weighing regional fit before deciding.

Where Xobin fits

A self-serve, budget-friendly option for teams that want to get started quickly without a large upfront commitment or an enterprise sales process.

Where the gap shows up

Like other budget-tier assessment platforms, Xobin's presence and localized support tend to be thinner in markets like Türkiye, Azerbaijan, and the wider Caucasus and Central Asia — a real consideration if regional trust and support responsiveness matter to your hiring team, not just sticker price.

Where TheyTest differs

  • Real, established regional customer base — 100+ B2B customers across Türkiye, Azerbaijan, and neighboring markets, with named case studies like Clopos and Simbrella.
  • Monthly billing with no annual contract — Basic at $119/mo, Pro at $179/mo — keeping budget-tier pricing while including video verification and AI-cheating detection standard.
  • Support and sales conversations grounded in regional hiring realities, not a one-size-fits-all global self-serve flow.

Bottom line

If you're comparing purely on entry price and hiring in a market Xobin already serves well, it's a reasonable low-cost option. If regional presence and support matter as much as price, TheyTest is worth comparing directly.

TheyTest offers a 14-day free trial with full Pro features, no credit card required.

TODO before publishing: this post relies on the general "budget alternative" positioning from internal competitive research, which does not include Xobin-specific pricing or feature details — verify Xobin's actual current pricing, feature set, and regional presence directly before publishing, and add any genuinely distinguishing facts found. Do not publish as-is if no Xobin-specific research has been done.